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INTRODUCTION 
 
 
India is frequently referred to as the diabetic capital of the world as it has the 
highest number of cases in the world. 
The worldwide prevalence of diabetes has risen dramatically over the past 
two decades, from an estimated 30 million cases in 1985 to 177 million in 
2000.1 Based on current trends greater than 360 million individuals worldwide 
will have diabetes by the year 2030.1 
 India had around 31.7 million cases in year 2000 which is expected to rise 
alarmingly to around 79.4 million in 2030 by which time every fifth diabetic 
subject in the world would be an Indian.1 Indian studies puts these numbers at 
a much higher levels from estimated 51 million in 2010 to 87 million in 2030.2 
 The prevalence rate in India varies among urban and rural population. In the 
urban population, an Indian Council of Medical Research (ICMR) study in 1972 
reported a prevalence of 2.3%.3 which rose to 12.1% in the year 2000.4 More 
recently,  estimates from a nationwide surveillance study of T2DM  found  a 
prevalence of 7.3% in urban areas  & 3.2% in peri-urban/slum areas (urban 
fringes).5 In the rural population, an early study in 1991  indicated that the 
prevalence rate  ranged from 0.4-1.5%  in Delhi.6  A  multicentric study in 2008 
estimated the prevalence to be 3.1%.5 
In Tamilnadu the prevalence in 2008 is 18.6% in urban areas and 9.1% in rural 
areas.7 
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The incidence of T2DM in the urban south Indian population was 20.2 per 
1,000 person years.5 
Diabetes is a major cause of mortality, but several studies indicate that 
diabetes is likely underreported as a cause of death. In the United States, 
diabetes was listed as the seventh leading cause of death in 2007; a recent 
estimate suggested that diabetes was the fifth leading cause of death 
worldwide and was responsible for almost 4 million deaths in 2010 (6.8% of 
deaths were attributed to diabetes worldwide). 
In India diabetes is responsible for 109 thousand deaths, 1.157 million years of 
life lost and 2.263 million disability adjusted life years (DALYs) during 2004.8-9 
WHO estimates that mortality from diabetes, heart disease and stroke costs 
about $210 billion in India in the year 2005. Much of the heart disease and 
stroke in these estimates was linked to diabetes. WHO estimates that 
diabetes, heart disease and stroke together will cost about $ 333.6 billion over 
the next 10 years in India.  
Although the prevalence of both type 1 and type 2 diabetes is increasing 
worldwide, the prevalence of type 2 diabetes is rising much more rapidly 
because of increasing obesity and reduced activity levels. 
The real burden of the disease is however due to its macro and micro vascular 
complications. Macrovascular complications are the most important causes of 
morbidity, mortality and disability in people with Type 2 diabetes mellitus. 
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Coronary artery disease is the leading cause of death among adult diabetics 
and accounts for about three times as many deaths among diabetics as among 
non-diabetics.10  
it is now being increasingly appreciated that the traditional risk factors 
(smoking, obesity, hypercholesterolemia, family history, physical inactivity, 
diabetes mellitus, hypertension) for cardiovascular disease  may account for 
only one half to two thirds of the actual risk.  It becomes important to try and 
identify other risk factors, especially those that can be easily modified or 
corrected. Some of the factors whose role is being seriously investigated 
include estrogen deficiency, lipoprotein(a), plasma fibrinogen, plasminogen-
activator inhibitor type 1, endogenous tissue plasminogen activator (tPA), C-
reactive protein , and homocysteine. 
Fibrinogen is one such factor. It is the precursor of fibrin and an important 
determinant of blood viscosity and platelet aggregation. Elevation of plasma 
viscosity due to increase in fibrinogen concentration significantly contributes 
to the  microvascular disorder in diabetics.13-14 Similarly many studies have 
shown elevated fibrinogen to be an important risk factor for coronary artery 
disease.15-17 Evidence also suggests that fibrinogen may be involved in the 
development of atherosclerotic lesions beginning with the early stages of 
plaque formation.11  
To conclude among the various hematological factors, elevated fibrinogen as a 
risk factor in diabetes plays an important role in the development of 
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complications.18 Fibrinogen levels can be reduced considerably by life style 
interventions and probably drugs there is possibility that measurement of 
fibrinogen may help in disease prediction or prevention.12, 56 
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AIMS AND OBJECTIVES 
1. To estimate the levels of plasma fibrinogen in patients with diabetes 
mellitus. 
2. To compare the levels of fibrinogen in patients with diabetes alone, 
diabetes with microvascular complications, diabetes with 
macrovascular complications. 
3. To correlate levels of fibrinogen with age, body weight, Body Mass 
Index, total cholesterol and HbA1c levels. 
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REVIEW OF LITERATURE 
 
Introduction 
Diabetes mellitus (DM) refers to a group of common metabolic disorders that 
is characterized by chronic hyperglycemia. Several distinct types of DM are 
caused by a complex interaction of genetics and environmental factors. The 
metabolic dysregulation associated with DM causes secondary 
pathophysiologic changes in multiple organ systems commonly the eyes, 
kidney, heart and blood vessels. With an increasing incidence worldwide, DM 
will be a leading cause of morbidity and mortality for the foreseeable future. 
The word Diabetes in Greek means – “I run through Siphon”.  Indian name for 
Diabetes is Madhumeha – Honey in rain. In 16th century, Susrutha in the 
Sanskirit book of surgery, and Charaka in the Sanskirit book of medicine have 
mentioned about Diabetes. The first person -Vaidys – tested the urine of 
diabetic patients. 
 
 
Classification 
DM is classified on the basis of the pathogenic process that leads to 
hyperglycemia. The two broad categories of DM are designated type 1 and 
type 2 
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Etiologic Classification of Diabetes Mellitus.19 
 
 
I. Type 1 diabetes (beta cell destruction, usually leading to absolute insulin 
deficiency)  
A. Immune-mediated 
B. Idiopathic 
II. Type 2 diabetes (may range from predominantly insulin resistance with 
relative insulin deficiency to a predominantly insulin secretory defect with 
insulin resistance) 
III. Other specific types of diabetes 
A. Genetic defects of beta cell function  
B. Genetic defects in insulin action 
C. Diseases of the exocrine pancreas—pancreatitis, pancreatectomy, 
neoplasia.  
 D.Endocrinopathies- acromegaly, Cushing's syndrome, glucagonoma etc. 
E. Drug- or chemical-induced 
F. Infections—congenital rubella, cytomegalovirus, coxsackievirus. 
G. Uncommon forms of immune-mediated diabetes— "stiff-person" 
syndrome etc 
H. Other genetic syndromes sometimes associated with diabetes like Turners 
IV. Gestational diabetes mellitus (GDM) 
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Diagnosis 
Glucose tolerance is classified into three broad categories:  
(1)Normal glucose homeostasis: 
 A Fasting plasma glucose < 100 mg/dl (5.6 mmol/l) b, a plasma glucose < 140 
mg/dl (11.1 mmol/L) following an oral glucose tolerance test d, and an HbA1C 
< 5.6%c are considered to define normal glucose tolerance. 
 (2)Diabetes Mellitus: The International Expert Committee with members 
appointed by the American Diabetes Association, the European Association 
for the Study of Diabetes, and the International Diabetes Federation has 
issued the following diagnostic criteria. 
Criteria for the Diagnosis of Diabetes Mellitus 
 
1.Symptoms of diabetes plus random blood glucose concentration ≥11.1 
mmol/l (200 mg/dl) a or  
2.Fasting plasma glucose ≥7.0 mmol/l(126 mg/dl)b or  
3.HbA1c > 6.5%cor  
4.Two-hour plasma glucose ≥11.1 mmol/l (200 mg/dl) during an oral glucose 
tolerance test d 
 
 
a Random is defined as without regard to time since the last meal. 
b Fasting is defined as no caloric intake for at least 8 h.  
c The test should be performed in a standard laboratory. 
d The test should be performed using a glucose load containing the equivalent 
of 75 g anhydrous glucose dissolved in water. 
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(3)Abnormal glucose homeostasis 
It is defined as  
(a) A Fasting plasma glucose = 5.6–6.9 mmol/l (100–125 mg/dl), is called as 
Impaired Fasting Glucose (IFG) (World Health Organization uses an FPG of 6.1–
6.9 mmol/l (110–125 mg/dl);  
(b)Plasma glucose levels between 7.8 and 11 mmol/l (140 and 199 mg/dl) 
following an oral glucose challenge, which is called impaired glucose tolerance 
(IGT);  
 (3) HbA1c of 5.7–6.4%.  
A HbA1c of 5.7–6.4%, IFG, and IGT do not identify the same individuals, but 
individuals in all three groups are at greater risk of progressing to type 2 
diabetes and have an increased risk of cardiovascular disease. The term 
"prediabetes," "increased risk of diabetes" (ADA), or "intermediate 
hyperglycemia" (WHO) are used for this category. 
 The current criteria for the diagnosis of DM emphasize that the HbA1c or the 
FPG as the most reliable and convenient tests for identifying DM in 
asymptomatic individuals. Oral glucose tolerance testing, although still a valid 
means for diagnosing DM, is not often used in routine clinical care 
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Screening 
Widespread Fasting Plasma Glucose (FPG) or HbA1C as a screening test for 
type 2 DM is recommended because  
(a) A large number of individuals who meet the current criteria for DM are 
asymptomatic. 
(b) Epidemiologic studies suggest that type 2 DM may be present up to a 
decade before diagnosis. 
(c) Some individuals with type 2 DM have one or more diabetes-specific 
complications at the time of their diagnosis. 
(d) Treatment of type 2 DM may favorably alter the natural history of DM.  
 
The ADA recommends screening all individuals > 45 years every 3 years and 
screening individuals at an earlier age if they are overweight [body mass index 
(BMI) >25 kg/m2] and have one additional risk factor for diabetes . In contrast 
to type 2 DM, a long asymptomatic period of hyperglycemia is rare prior to 
the diagnosis of type 1 DM.  
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Risk factors for type 2 Diabetes Mellitus 
The risk factors for developing DM are as under. 
 
Risk Factors for Type 2 Diabetes Mellitus19 
 
 
Family history of diabetes (i.e., parent or sibling with type 2 diabetes) 
Obesity (BMI ≥25 kg/m2) 
Physical inactivity 
Race/ethnicity (e.g., African American, Latino, Native American, Asian American, 
Pacific Islander) 
Previously identified with IFG, IGT, or an A1C of 5.7–6.4% 
History of GDM or delivery of baby >4 kg  
Hypertension (blood pressure ≥140/90 mmHg) 
HDL cholesterol level <35 mg/dL (0.90 mmol/L) and/or a triglyceride level >250 
mg/dL (2.82 mmol/L) 
Polycystic ovary syndrome or acanthosis nigricans 
History of cardiovascular disease 
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TYPE 1 DIABETES 
 
Introduction 
It constitutes roughly 5 – 10% of all the diabetic patients. Previously it was 
called as Insulin dependent Diabetes mellitus (IDDM). Rates of type 1 diabetes 
are increasing by around 2 – 2.5% per year worldwide and is common in 
males. 
Type 1 DM usually starts in children aged 4 years or older, usually abruptly, 
with the peak incidence of onset at age 11-13 years. Also, a relatively high 
incidence exists in people in their late 30s and early 40s, when the disease 
tends to present in a less aggressive manner (ie, early hyperglycemia without 
ketoacidosis and gradual onset of ketosis) referred to as latent autoimmune 
diabetes of the adult (LADA).28 
Pathogenesis 
Type 1 DM is the result of interactions of genetic, environmental, and 
immunologic factors that ultimately lead to the destruction of the pancreatic 
beta cells and insulin deficiency.  
Immunological Factors 
 Most (around 85%), individuals have evidence of islet-directed autoimmunity. 
Prevalence is increased in patients with other autoimmune diseases, such as 
Graves disease, Hashimoto thyroiditis, and Addison disease. Prevalence of 
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type 1 diabetes autoantibodies and newly diagnosed type 1 diabetes is higher 
in patients with autoimmune thyroiditis.21 Some individuals have  type 1 DM 
lack immunologic markers indicative of an autoimmune process . 
 Islet cell autoantibodies (ICAs) are a composite of several different antibodies 
directed at pancreatic islet molecules such as GAD, insulin, IA-2/ICA-512, and 
ZnT-8, and serve as a marker of the autoimmune process of type 1 DM.  
Assays for autoantibodies to GAD-65 are commercially available. Testing for 
ICAs can be useful in classifying the type of DM as type 1 and in identifying 
non diabetic individuals at risk for developing type 1 DM. Islet cell antibodies 
are present in the majority of individuals (>85%) diagnosed with new-onset 
type 1 DM, in a significant minority of individuals with newly diagnosed type 2 
DM (5–10%), and occasionally in individuals with GDM (<5%).  
Genetic Factors 
The concordance of type 1 DM in identical twins ranges between 40 and 60%, 
compared to 70 – 90 % in type2 diabetes mellitus. Most individuals with type 
1 DM have the HLA DR3 and/or DR4 haplotype. Refinements in genotyping of 
HLA loci have shown that the haplotypes DQA1*0301, DQB1*0302, and 
DQB1*0201 are most strongly associated with type 1 DM.  
In addition to MHC class II associations, genome association studies have 
identified at least 20 different genetic loci that contribute susceptibility to 
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type 1 DM (polymorphisms in the promoter region of the insulin gene, the 
CTLA-4 gene, interleukin-2 receptor, CTLA4, and PTPN22, etc.).  
Genes that confer protection against the development of the disease also 
exist. The haplotype DQA1*0102, DQB1*0602 is extremely rare in individuals 
with type 1 DM (<1%) and appears to provide protection from type 1 DM. 
Environmental and Other Factors 
Potential triggers for immunologically mediated destruction of the beta cells 
include viruses (eg, mumps, rubella, coxsackievirus B4), toxic chemicals, 
exposure to cow’s milk in infancy, and cytotoxins. A meta-analysis suggests a 
significant association between enterovirus infection and autoimmune/type 1 
DM.22 
Infant weight velocity has a small indirect effect on adult insulin resistance, 
and this is primarily mediated through its effect on BMI and waist 
circumference.23 
Intensive dose statin therapy was associated with increased risk of new onset 
diabetes compared with moderate dose in a pooled analysis of data from 5 
statin trials.24 
Amino acid metabolism also plays a key role in the pathogenesis of diabetes. 
Amino acid profiles could help assess risk of developing diabetes.25 
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Recent evidence suggests a role for vitamin D in the pathogenesis and 
prevention of diabetes mellitus. Vitamin D deficiency is also an important 
independent predictor of development of coronary artery calcification in 
individuals with type 1 DM.26-27 
The morbidity and mortality associated with diabetes are related to the short- 
and long-term complications. Such complications include hypoglycemia and 
hyperglycemia, increased risk of infections, microvascular complications (eg, 
retinopathy, nephropathy), neuropathic complications, and macrovascular 
complications like ischemic heart disease, cerebral vascular disease, 
peripheral vascular disease. 
 
TYPE 2 DIABETES MELLITUS 
Introduction 
It constitutes around 85 – 90 % of all diabetes mellitus. Previously called as 
Non insulin dependent diabetes, Adult onset diabetes etc. 
Etiology and Pathogenesis 
Insulin resistance and abnormal insulin secretion are central to the 
development of type 2 DM. Although the primary defect is controversial, most 
studies support the view that insulin resistance precedes an insulin secretory 
defect but that diabetes develops only when insulin secretion becomes 
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inadequate. A recent study indicates Beta cell function happens early in the 
pathological process and does not necessarily follow stage of insulin 
resistance.29 
Because they retain the ability to secrete some endogenous insulin, they are 
considered to require insulin but not to depend on insulin. In the progression 
from normal glucose tolerance to abnormal glucose tolerance, postprandial 
blood glucose levels increase first; eventually, fasting hyperglycemia develops 
as suppression of hepatic gluconeogenesis fails. 
Genetic Considerations 
Type 2 DM has a strong genetic component. The concordance of type 2 DM in 
identical twins is between 70 and 90%. Individuals with a parent with type 2 
DM have an increased risk of diabetes; if both parents have type 2 DM, the 
risk approaches 40%.  The disease is polygenic and multifactorial, since in 
addition to genetic susceptibility, environmental factors (such as obesity, 
nutrition, and physical activity) modulate the phenotype. The genes that 
predispose to type 2 DM are incompletely identified, but recent genome-wide 
association studies have identified a large number of genes that convey a 
relatively small risk for type 2 DM. Most prominent is a variant of the 
transcription factor 7–like 2 gene that has been associated with type 2 
diabetes in several populations and with impaired glucose tolerance in one 
population at high risk for diabetes. Genetic polymorphisms associated with 
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type 2 diabetes have also been found in the genes encoding the peroxisome 
proliferators–activated receptor-γ, inward rectifying potassium channel, zinc 
transporter, IRS, and calpain 10. The mechanisms by which these genetic loci 
increase the susceptibility to type 2 diabetes are not clear. 
Other factors 
(a) About 90% of patients who develop type 2 diabetes mellitus are obese. 
However, a large, population-based, prospective study has shown that an 
energy-dense diet may be a risk factor for the development of diabetes that is 
independent of baseline obesity.30 Compared with persons of European 
ancestry, persons of Asian ancestry are at increased risk for diabetes at lower 
levels of overweight.31 
(b) Hypertension and prehypertension are associated with greater risk of 
developing diabetes in whites compared with African Americans.32 
(c) Abnormal in utero environment resulting in low birth weight may 
predispose some individuals to develop type 2 diabetes mellitus.33-34 
Some forms of diabetes, however, have a clear association with genetic 
defects. The syndrome previously known as maturity onset diabetes of youth 
(MODY) has now been reclassified as a variety of defects in beta-cell function. 
These defects account for 2-5% of individuals with type 2 diabetes who 
present at a young age and have mild disease. The trait is autosomal dominant 
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and can be screened for through commercial laboratories. To date, 6 
mutations have been identified:  
 HNF-4-alpha 
 Glucokinase gene 
 HNF-1-alpha 
 IPF-1 
 HNF-1-beta 
 NEUROD1 
During the induction of insulin resistance, such as is seen after high-calorie 
diet, steroid administration, or physical inactivity, increased glucagon levels 
and increased glucose-dependent insulinotropic polypeptide (GIP) levels 
accompany glucose intolerance; however, postprandial glucagon like peptide-
1 (GLP-1) response is unaltered.5 This has physiologic implications; for 
example, if the GLP-1 level is unaltered, GLP-1 may be a target of therapy in 
the states mentioned above.  
Chronic Complications of DM 
The chronic complications of DM affect many organ systems and are 
responsible for the majority of morbidity and mortality associated with the 
disease. The risk of chronic complications increases with the duration and 
degree of hyperglycemia; they usually do not become apparent until the 
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second decade of hyperglycemia in patients with type 1 DM but  type 2 DM 
patients often have complications at the time of diagnosis. 
Chronic complications can be divided into vascular and nonvascular 
complications. 
 The vascular complications of DM are further subdivided into microvascular 
and macrovascular complication. 
Chronic Complications of Diabetes Mellitus 
 
Microvascular 
Eye disease 
Retinopathy (nonproliferative/proliferative) 
Macular edema 
Neuropathy 
Sensory and motor (mono- and polyneuropathy) 
Autonomic 
Nephropathy 
Macrovascular 
Coronary heart disease 
Peripheral arterial disease 
Cerebrovascular disease 
Other 
Gastrointestinal (gastroparesis, diarrhea) 
Genitourinary (uropathy/sexual dysfunction) 
Dermatologic 
Infectious 
Cataracts 
Glaucoma 
Periodontal disease 
Hearing loss 
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Although the pathophysiology differs between the types of diabetes, it is 
similar in most of the complications, including microvascular, macrovascular, 
and neuropathic.  
Hyperglycemia appears to be the determinant of microvascular and metabolic 
complications.  
Macrovascular disease, however, is much less related to glycemia but a good 
glcemic control may produce improvement in the lipid profile.95  
Insulin resistance with concomitant lipid abnormalities ( elevated levels of 
small dense low-density lipoprotein cholesterol [LDL-C] particles, low levels of 
high-density lipoprotein cholesterol [HDL-C], elevated levels of triglycerides) 
and thrombotic abnormalities (ie, elevated type-1 plasminogen activator 
inhibitor [PAI-1], elevated fibrinogen), as well as conventional atherosclerotic 
risk factors (eg, family history, smoking, hypertension,  obesity, sedentary life 
style), determine cardiovascular risk.  
Unlike liver and smooth muscle, insulin resistance is not associated with 
increased myocardial lipid accumulation.35Persistent lipid abnormalities 
remain in patients with diabetes despite evidence supporting benefits of lipid-
modifying drugs. Statin dose up-titration and the addition of other lipid-
modifying agents are needed.36 
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Increased cardiovascular risk appears to begin earlier to the development of 
frank hyperglycemia, presumably because of the effects of insulin resistance. 
Stern37 in 1996 and Haffner and D'Agostino in 199938developed the "ticking 
clock" hypothesis of complications, suggesting that the clock starts ticking for 
microvascular risk at the onset of hyperglycemia, while the clock starts ticking 
for macrovascular risk at some antecedent point, presumably with the onset 
of insulin resistance. 
 
Mechanisms producing chronic complications 
 Although chronic hyperglycemia is an important etiologic factor leading to 
complications of DM mainly the microvascular ones, the mechanisms by which 
it leads on to these varied involvement of multiple organ system is not fully 
understood. There are four prominent theories, though not mutually 
exclusive, have been proposed to explain how hyperglycemia may be leading 
to the chronic complications of DM. 
(1)Formation of advanced glycosylation end products (AGEs) 
This occurs due to nonenzymatic glycosylation of intra- and extracellular 
proteins from the interaction of glucose with amino groups on proteins. AGEs 
have been shown to cross-link proteins (e.g., collagen, extracellular matrix 
proteins), accelerate atherosclerosis, promote glomerular dysfunction, reduce 
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nitric oxide synthesis, induce endothelial dysfunction, and alter extracellular 
matrix composition and structure. The serum level of AGEs correlates with the 
level of glycemia, and these products accumulate as the glomerular filtration 
rate (GFR) declines. 
(2)Sorbitol pathway 
Hyperglycemia increases glucose metabolism via the sorbitol pathway by the 
enzyme aldose reductase. Increased sorbitol concentration alters redox 
potential, increases cellular osmolality, generates reactive oxygen species, and 
also leads to other types of cellular dysfunction. However, using aldose 
reductase inhibitors has not shown significant beneficial effects. 
(3)Diacylglycerol pathway 
Hyperglycemia increases the formation of diacylglycerol leading to activation 
of protein kinase C which alters the transcription of genes for fibronectin, type 
IV collagen, contractile proteins, and extracellular matrix proteins in 
endothelial cells and neurons. Inhibitors of PKC are being studied in clinical 
trials. 
(4)Hexosamine Pathway 
Hyperglycemia increases the flux through the hexosamine pathway, which 
generates fructose-6-phosphate, which may alter function by glycosylation of 
proteins such as endothelial nitric oxide synthase or by changes in gene 
expression of transforming growth factor or plasminogen activator inhibitor-1 
(PAI-1). 
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Growth factors appear to play an important role in some DM-related 
complications. 
 Vascular endothelial growth factor A (VEGF-A) is increased locally in 
diabetic proliferative retinopathy. 
  TGF- is increased in diabetic nephropathy and stimulates production 
of collagen and fibronectin by mesangial cells. 
  Other growth factors, such as platelet-derived growth factor, 
epidermal growth factor, insulin-like growth factor I, growth hormone, 
basic fibroblast growth factor, and even insulin, have been suggested 
to play a role in DM-related complications.  
An emerging hypothesis is that hyperglycemia leads to epigenetic changes in 
the affected cells. 
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Diabetic Retinopathy 
DM is one of the leading cause of blindness in India. In India, the prevalence of 
Diabetic Retinopathy amongst diabetics is 17–27%. Prevalence of diabetic 
retinopathy at the time of diagnosis is 7.3%.95 Individuals with DM are 25 
times more likely to become legally blind than individuals without DM.  
Diabetic retinopathy is classified into two stages:  
(1)Nonproliferative diabetic retinopathy  
Usually appears late in the first decade or early in the second decade of the 
disease and is marked by retinal vascular microaneurysms, blot hemorrhages, 
and cotton-wool spots and progresses to more extensive disease, 
characterized by changes in venous vessel caliber, intraretinal microvascular 
abnormalities, and more numerous microaneurysms and hemorrhages. The 
pathophysiologic mechanisms invoked in nonproliferative retinopathy include 
loss of retinal pericytes, increased retinal vascular permeability, alterations in 
retinal blood flow, and abnormal retinal microvasculature, all of which lead to 
retinal ischemia. 
(2)Proliferative diabetic retinopathy 
The appearance of neovascularization in response to retinal hypoxemia is the 
hallmark of proliferative disease. These newly formed vessels appear near the 
optic nerve and/or macula and rupture easily, leading to vitreous hemorrhage, 
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fibrosis, and ultimately retinal detachment.  Hence it is important to detect 
early and treat so as to prevent its progression.  
(3).Clinically significant macular edema can occur when only nonproliferative 
retinopathy is present. Fluorescein angiography is useful to detect macular 
edema, which is associated with a 25% chance of moderate visual loss over 
the next 3 years. 
Duration of DM and degree of glycemic control are the best predictors of the 
development of retinopathy; hypertension is also a risk factor.  
Diabetic Nephropathy 
Diabetic nephropathy is the leading cause of end stage renal disease (ESRD) 
and a leading cause of DM-related morbidity and mortality. Both 
microalbuminuria and macroalbuminuria in individuals with DM are 
associated with increased risk of cardiovascular disease. Individuals with 
diabetic nephropathy commonly have diabetic retinopathy. 
The pathogenesis of diabetic nephropathy is related to chronic hyperglycemia. 
The mechanisms by which chronic hyperglycemia leads to end stage renal 
disease (ESRD) is not fully understood. It is probably due to 
  The effects of soluble factors (growth factors, angiotensin II, 
endothelin, AGEs).  
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 Hemodynamic alterations in the renal microcirculation like glomerular 
hyperfiltration or hyperperfusion and  increased glomerular capillary 
pressure. 
  Structural changes in the glomerulus like increased extracellular 
matrix, basement membrane thickening, mesangial expansion and 
fibrosis. 
Smoking accelerates the decline in renal function.  
The natural history of diabetic nephropathy is characterized by a fairly 
predictable sequence of events that was initially defined for individuals with 
type 1 DM but appears to be similar in type 2 DM.  
Glomerular hyperperfusion and renal hypertrophy occur in the first years after 
the onset of DM and are associated with an increase of the GFR which then 
return to normal during the first 5 years of DM. 
After 5–10 years of type 1 DM, nearly 40% of individuals begin to excrete 
small amounts of albumin in the urine. Microalbuminuria is defined as 30–299 
mg/d in a 24-h collection or 30–299 g/mg creatinine in a spot collection 
(preferred method). Although the appearance of microalbuminuria in type 1 
DM is an important risk factor for progression to macroalbuminuria (>300 
mg/d or > 300 g/mg creatinine) Microalbuminuria is a risk factor for 
cardiovascular disease. Once macroalbuminuria is present, there is a steady 
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decline in GFR, and nearly 50% of individuals reach ESRD in 7–10 years. Once 
macroalbuminuria develops, blood pressure rises slightly and the pathologic 
changes are likely to be irreversible. 
The nephropathy that develops in type 2 DM differs from that of type 1 DM in 
the following respects: 
 (1)Microalbuminuria or macroalbuminuria may be present when type 2 DM is 
diagnosed, reflecting its long asymptomatic period. 
 (2)Hypertension more commonly accompanies microalbuminuria or 
macroalbuminuria in type 2 DM. 
 (3)Microalbuminuria is less predictive of diabetic nephropathy and 
progression to macroalbuminuria in type 2 DM. 
Diabetic Neuropathy 
Diabetic neuropathy occurs in 50% of individuals with long-standing type 1 
and type 2 DM. It may manifest as polyneuropathy, mononeuropathy, and/or 
autonomic neuropathy. The development of neuropathy correlates with the 
duration of diabetes and glycemic control. Both myelinated and unmyelinated 
nerve fibers are lost. Because the clinical features of diabetic neuropathy are 
similar to those of other neuropathies, the diagnosis of diabetic neuropathy 
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should be made only after other possible etiologies are excluded. It can be of 
many types. 
(1)Polyneuropathy/Mononeuropathy 
The most common form of diabetic neuropathy is distal symmetric 
polyneuropathy. It most frequently presents with distal sensory loss, 
hyperesthesia, paresthesia, and dysesthesia . Neuropathic pain develops in 
some of these individuals typically involves the lower extremities, is usually 
present at rest, and worsens at night. As diabetic neuropathy progresses, the 
pain subsides and eventually disappears, but a sensory deficit in the lower 
extremities persists. Physical examination reveals sensory loss, loss of ankle 
reflexes, and abnormal position sense. 
Diabetic polyradiculopathy is a syndrome characterized by severe disabling 
pain in the distribution of one or more nerve roots. It may be accompanied by 
motor weakness. Intercostal or truncal radiculopathy causes pain over the 
thorax or abdomen. Involvement of the lumbar plexus or femoral nerve may 
cause severe pain in the thigh or hip and may be associated with muscle 
weakness in the hip flexors or extensors (diabetic amyotrophy). Diabetic 
polyradiculopathies are usually self-limited and resolve over 6–12 months. 
Mononeuropathy is less common than polyneuropathy in DM and presents 
with pain and motor weakness in the distribution of a single nerve.  
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Involvement of the third cranial nerve is most common and is heralded by 
diplopia. Other cranial nerves IV, VI, or VII are also affected. Mononeuritis 
multiplex may also occur. 
(2)Autonomic Neuropathy 
Individuals with long-standing DM may develop signs of autonomic 
dysfunction involving the cholinergic, noradrenergic, and peptidergic 
(peptides such as pancreatic polypeptide, substance P, etc.) systems. 
Autonomic neuropathies affecting the cardiovascular system cause a resting 
tachycardia and orthostatic hypotension may be responsible for sudden 
cardiac death. Gastroparesis, bladder-emptying abnormalities, hyperhidrosis 
of the upper extremities and anhidrosis of the lower extremities and an 
inability to sense hypoglycemia appropriately - hypoglycemia unawareness 
may also occur. 
Lower Extremity Complications 
DM is the leading cause of non traumatic lower extremity amputation. Foot 
ulcers and infections are also a major source of morbidity in individuals with 
DM. The reason for the increased incidence of these disorders in DM is due to 
several pathogenic factors: neuropathy, abnormal foot biomechanics, 
Peripheral vascular disease, and poor wound healing. The peripheral sensory 
neuropathy interferes with normal protective mechanisms and allows the 
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patient to sustain major or repeated minor trauma to the foot, often without 
knowledge of the injury. Disordered proprioception causes abnormal weight 
bearing while walking and subsequent formation of callus or ulceration. Motor 
and sensory neuropathy lead to abnormal foot muscle mechanics and to 
structural changes in the foot (hammertoe, claw toe deformity, prominent 
metatarsal heads, Charcot joint). Autonomic neuropathy results in anhidrosis 
and altered superficial blood flow in the foot, which promote drying of the 
skin and fissure formation. PAD and poor wound healing impede resolution of 
minor breaks in the skin, allowing them to enlarge and to become infected. 
Approximately 15% of individuals with type 2 DM develop a foot ulcer and a 
significant subset will ultimately undergo amputation (14–24% risk with that 
ulcer or subsequent ulceration).  
Risk factors for foot ulcers or amputation include: male sex, diabetes >10 
years' duration, peripheral neuropathy, abnormal structure of foot (bony 
abnormalities, callus, thickened nails), peripheral arterial disease, smoking, 
history of previous ulcer or amputation, and poor glycemic control. 
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Coronary Artery Disease 
Cardiovascular disease is increased in individuals with type 1 or type 2 DM. 
The Framingham Heart Study revealed a marked increase in Coronary artery 
disease (CAD), Myocardial infarction, Congestive heart failure, Peripheral 
vascular disease and sudden death in DM. The American Heart Association has 
designated DM as a "CHD risk equivalent." Type 2 diabetes patients without a 
prior MI have a similar risk for coronary artery related events as non diabetic 
individuals who have had a prior MI.  CHD is more likely to involve multiple 
vessels in individuals with DM. 
The increase in cardiovascular morbidity and mortality rates appears to be 
due to the synergism of hyperglycemia with other cardiovascular risk factors. 
Risk factors for macrovascular disease in diabetic individuals include 
dyslipidemia, hypertension, obesity, reduced physical activity, and cigarette 
smoking. 
The presence of complications - microalbuminuria, macroalbuminuria, an 
elevated serum creatinine, and abnormal platelet function also plays a role in 
development of macrovascular complications. 
Insulin resistance, as reflected by elevated serum insulin levels, is associated 
with elevated levels of plasminogen activator inhibitors ( PAI-1) and 
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fibrinogen, which enhances the coagulation process and impairs fibrinolysis, 
thus favoring the development of thrombosis. 
Because of the extremely high risk of cardiovascular disease in individuals, any 
diabetic patient who has symptoms suggestive of cardiac ischemia or 
peripheral or carotid arterial disease should undergo thorough evaluation. The 
absence of chest pain ("silent ischemia") is common, and so a thorough 
cardiac evaluation is mandatory when undergoing major surgical procedures. 
 In both the DCCT (type1 diabetes) and the UKPDS (type2 diabetes), 
cardiovascular events were not reduced by intensive treatment during the 
trial but were reduced at follow-up 10 to 17 years later termed legacy effect 
or metabolic memory. During the DCCT, an improvement in the lipid profile of 
individuals in the intensive group (lower total and LDL cholesterol, lower 
triglycerides) during intensive diabetes management was noted. Other trials 
have also failed to show any reduction in cardiovascular morbidity and 
mortality. 
The incidence of cerebrovascular disease is increased three times in 
individuals with DM than in non diabetics. The mechanisms operating in the 
development of coronary artery disease also acts here. 
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FIBRINOGEN AND DIABETES MELLITUS 
Introduction 
Fibrinogen is one of the most important coagulation factors in the final 
common pathway of coagulation. When fibrinogen is converted to fibrin, it 
forms the structural meshwork that consolidates an initial platelet plug into a 
solid hemostatic clot. The physiologic importance of fibrinogen is 
demonstrated by the bleeding diathesis associated with afibrinogenemia61, 62 
and some dysfibrinogenemias.63Other dysfibrinogenemias are associated with 
thromboembolic disease .62, 64  
Fibrinogen is a dimeric glycoprotein synthesized in the liver and has a 
molecular weight of 340,000. It I made up of 2 subunits. Each subunit contains 
three disulfide-linked polypeptide chains69 referred to as the A (66.5kD), B 
(52kD), and γ (46.5kD) chains. Aµ, Bb, and γ are composed of 610, 461, and 
411 amino acids, respectively. Fibrinopeptides A and B are released from the 
amino-termini of the A and B chains by thrombin cleavage of the Argl6-
Glyl7 and Argl4-Glyl5 bonds, respectively to form the fibrin.70The genes for the 
three chains of fibrinogen are found within a 50-kb length of DNA on 
chromosome 4 at q23-q32.71  
 It is found in plasma and in platelet -granules. In the platelets it is taken up 
from plasma by endocytosis mediated by glycoprotein IIb/IIIa. Platelet 
fibrinogen lacks chain. The plasma half-life of fibrinogen is 3 to 5 days.65 
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Fibrinogen plays an important role in the following processes. 
1. The soluble fibrinogen molecule is converted into insoluble fibrin during the 
final common pathway of coagulation which stabilizes the initially formed 
platelet plug. 
2. The polymerized fibrin acts as a template for the activation of the 
fibrinolytic system, which regulates fibrin deposition and clot dissolution. 
3. Fibrinogen binds to cells such as platelets and causes platelet aggregation 
and to endothelial cells, where it participates in tissue repair. 
Hyperfibrinogenemia 
Fibrinogen plays a very crucial role in atherosclerosis and thrombosis related 
phenomenon like hemostasis, inflammation, aggregation of platelets, blood 
viscosity, smooth muscle proliferation and fibrinolysis. Though it is considered 
as a marker for the presence of vascular disease, it remains controversial 
whether fibrinogen is a cause or merely an association with the 
atherosclerotic process.72 
 Fibrinogen is an acute phase reactant, and its synthesis can be increased up 
to 20-fold with a strong inflammatory stimulus.66, 67IL-6 is an important 
mediator of increased fibrinogen synthesis during an acute phase response,68 
and IL-6 secretion can be up-regulated by fibrin degradation products. Thus, 
elevated fibrinogen levels may be a reflection of the low-grade inflammation 
associated with vascular disease. On the contrary, increased fibrinogen levels 
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(due to inflammation or other causes) may be responsible for the 
pathogenesis of vascular lesions, acting as a risk factor for the atherosclerotic 
disease and contribute to its progression. Moreover, fibrinogen and fibrin 
degradation products may enhance the inflammation in the vascular lesions 
by regulating cytokine mediated action and  leukocyte-endothelial 
interactions.73 A low grade inflammation secondary to Chlamydia or H.pylori 
infection have been suggested to raise fibrinogen levels and thus increase 
cardiovascular mortality and morbidity.86 
One of the significant and common conditions associated with both elevated 
fibrinogen level and cardiovascular disease are type 2 diabetes mellitus and 
the insulin resistance syndrome.74, 75  
Why type 2 diabetes mellitus produces elevated fibrinogen? The mechanisms 
leading to hyperfibrinogenemia in type 2 diabetes mellitus have not been 
elucidated so far. The potential mechanisms suggested include that of a low-
grade inflammation, hyperinsulinemia and albuminuria.76-78 
Zanetti et al and Schrem et al have suggested that the following mechanism -
In diabetes patients develop albuminuria which leads to hypoalbuminemia 
leading to decrease in plasma oncotic pressure which in turn stimulates 
hepatic protein synthesis, though synthesis of all the plasma protein, the 
synthesis of fibrinogen is increased to a greater extent associated with a 
decreased clearance and this increased levels of fibrinogen is responsible for 
cardiovascular adverse effects.77, 82 
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Others have reported that fibrinopeptide is positively related to glucose and 
this is probably how hyperglycemia leads to elevated fibrinogen levels.83-84 
There is also controversy whether elevated fibrinogen levels are a 
consequence of Diabetic nephropathy and subsequent loss of albumin or 
nephropathy is worsened by elevated fibrinogen.85 
Researchers have proposed the existence of “insulin resistance genes” which 
may be responsible for insulin resistance as well as hyperfibrinogenemia.79The 
putative genes include Lipoprotein lipase gene and the  fibrinogen gene.80-81. 
 
Multiple factors affect fibrinogen levels. It increases with age, body mass 
index, smoking, and post menopause, low-density-lipoprotein (LDL) 
cholesterol, lipoprotein (a) and leukocyte count. It decreases with physical 
activity87, moderate alcohol intake88, increased high-density-lipoprotein (HDL) 
cholesterol, and with hormone replacement therapy (HRT).89-90Higher levels of 
plasma fibrinogen were seen in non-drinkers or who drank > 60 g of alcohol 
per day.88 
Interventions to lower fibrinogen levels 
Lifestyle modifications can alter fibrinogen level, of which smoking cessation is 
by far the most effective; weight or stress reduction or an increase in regular 
physical activity has less effects; dietary modifications seems to have even less 
effect, moderate alcohol consumption causes a small reduction.93 
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Among the oral fibrinogen reducing medications, Fibrates (e.g. Bezafibrate 
reduces increased fibrinogen by around 40%), and Ticlopidine (reduces about 
15%) are effective only if fibrinogen was elevated. The efficacy of these drugs 
when the fibrinogen levels are normal has not been fully evaluated. Finally, 
intravenous fibrinolytic agents or heparin-induced extracorporeal low-density 
lipoprotein precipitation will lower fibrinogen dramatically; yet these methods 
are not indicated for this purpose alone and needs further studies .93 Aspirin 
therapy in low doses has no significant influence on plasma fibrinogen levels91 
 
Eriksson at al in a study involving 292 women the levels of fibrinogen levels 
were elevated in post menopausal women than pre menopausal women and 
in women not taking Hormone replacement therapy than in women taking 
Hormone Replacement therapy.43Thus Hormone replacement therapy (HRT) 
has a beneficial effect in lowering fibrinogen. 
Different antihypertensive drugs elicit different effects on fibrinogen and lipid 
profile, which variously influence the overall risk profile of these patients. 
Patients who were on ‘lipid-neutral (ACE-I, Ca-blocker, Angiotensin-II blocker) 
or lipid friendly (alpha-blocker) anti-hypertensive drugs had significantly lower 
plasma fibrinogen levels, when compared with those who were on ‘lipid-
hostile’ drugs (Beta-blocker, Thiazide diuretic).98 
A recent study has shown that elevated plasma fibrinogen (≥375 mg/dl) in the 
presence of diabetes mellitus and increased BMI (≥25 kg/m2) are associated 
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with lower platelet inhibition with Clopidogrel in patients with cardiovascular 
diseases.94 
In a study by Zhao et al involving 1300 Chinese diabetic subjects it was found 
that APTT values decreased and fibrinogen levels increased with increasing 
HbA1c values  and they recommended APTT and fibrinogen tests may 
potentially be used as screening tests for thrombotic complication risk in Type 
2 DM patients.97 
To conclude physiological importance of elevated plasma fibrinogen levels is 
not fully understood. There are various mechanisms through which fibrinogen 
may be involved in atherothrombosis. It may be due to rheological alterations, 
increased platelet aggregability, increased fibrin formation, and stimulation of 
vascular cell proliferation and migration but the association between  
fibrinogen and cardiovascular risk does not establish a cause-effect relation  
.Elevated fibrinogen levels, whatever the cause  may be like genetic,  
inflammation , or some other reason may cause a hypercoagulable state that 
could produce various adverse effects.92These adverse effects are more 
pronounced in diabetes mellitus. 
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METHODOLOGY 
Source of Data 
The study was conducted on patients with of Type 2 diabetes mellitus with or 
without complications admitted in Medical wards / attending outpatient 
department at Rajiv Gandhi Government General Hospital, Chennai. 
Study design                                             : Cross sectional study 
Ethical committee clearance                  : Obtained 
Competing interest                                 : Nil 
Financial support                                     : Nil 
Method of Collection of Data 
After obtaining consent the diabetic patients were subjected to detailed 
history, clinical examination and investigations as per the proforma. 
The following criteria were applied for selection of patients in the study group. 
Inclusion criteria 
1. Patients with Type2 diabetes mellitus (newly diagnosed or known cases) 
with or without microvascular or macrovascular complications 
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Exclusion criteria 
1. Patients with Coagulation abnormalities/ anticoagulant therapy. 
2. Smokers 
3. Alcoholic. 
4. Obese individuals with BMI > 30. 
5. Presence of features of active infection/inflammation like fever, diabetic 
foot ulcer, urinary tract infection. 
Lab  investigations 
1. Fasting and post prandial blood sugar. 
2. Fasting Lipid Profile. 
3. Early morning Spot urine Albumin by immune turbidimetry. 
4. HbA1c using H.P.L.C method. 
5. Plasma fibrinogen using automated optical light scattering method. 
6. Blood Urea and serum creatinine. 
7. Complete Blood Counts (Total count, Differential count, Hemoglobin, 
Erythrocyte sedimentation rate, hematocrit, and platelet count). 
8. Electrocardigram. 
9. Echocardiography (wherever necessary). 
10. Chest X ray. 
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Criteria/Case definition for classifying the patients 
(1) Diagnosis of Diabetes 
(a) Fasting Plasma Glucose > 126mg/dl and 2 Hours post prandial plasma 
glucose > 200mg/dl. 
(b) Known cases of type 2 Diabetes Mellitus taking/not taking medications. 
(2) Hypertension 
(a) Blood Pressure > 140/90 mm of Hg recorded in sitting posture on each of 2 
or more visits. 
(b) Known hypertensive patients taking/not taking medications. 
(3) Obesity 
Body Mass Index (BMI) = Weight in Kgs / Height in (Meter)² 
(a) Over weight -25 – 30 
(b) Obese > 30 
(4) Criteria for Microvascular complications 
Diabetic Retinopathy 
Fundus examination by o 
pthalmoscope after dilatation of pupils. 
(a) Non proliferating Diabetic Retinopathy: 
Microaneurysm, Haemorrhage, hard exudates 
(b) Proliferative Retinopathy 
 New vessels on disc (NVD) 
 New vessels elsewhere (NVE) 
42 
 
(c) Clinically significant macular edema (CSME) 
 Thickening of retina located 500μU/m from the center of macula. 
 Hard exudates with thickening of adjacent retina located 500μU/m 
from the center of macula. 
 Zone of retinal thickening of one disk area or larger in size, located one 
disc diameter from the center of macula. 
 Diabetic Nephropathy 
(a) Macroproteinuria: Protein excretion of > 500 mg/day. Microlbuminuria 
was tested by early morning spot albumin concentration and values greater 
than 2mg/dl were taken as significant in patients who did not have 
macroproteinuria.99 
(b) Serum Creatinine &Calculation of GFR done based on Cockcroft Gault 
formula  
Estimated creatinine clearance (ml/min) = 
          (140 – Age) X body weight (kg) 
----------------------------------------------------------------- 
             72 X Plasma Creatinine (mg/dL) 
(c) Ultrasonographic evidence of reduced kidney size. 
Diabetic Neuropathy 
History and Clinical examination was done for peripheral neuropathy, 
polyradiculopathy.  
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Criteria for Macrovascular complications 
Cardiovascular disease 
(a) History of Chest pain, breathlessness on exertion, prior myocardial 
infarction, congestive cardiac failure. 
(b)ECG features 
 Left ventricular hypertrophy. 
 Ischaemic heart disease – ST – T  changes 
 Features of old myocardial infarction. 
(c) Echocardiography (in selected situations only) 
 Regional wall motion abnormalities (RWMA) 
 Decreased Ejection Fraction 
Peripheral Vascular Disease 
Clinical examination of peripheral palpable arteries was done. Doppler study 
was done in relevant cases. 
Stroke 
History, clinical examination and imaging studies (CT/MRI) for stroke was 
done. 
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A total of 120 type 2 Diabetes mellitus patients were studied. Patients were 
divided into 3 groups:- 
Group 1: Patients had Diabetes mellitus alone without any microvascular or 
macrovascular complications. 
Group 2: Patients had Diabetes mellitus with predominant macrovascular 
complications (CVA / CAD). 
Group 3 Patients had predominant microvascular complications (Retinopathy, 
Nephropathy, Neuropathy). 
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OBSERVATIONS AND RESULTS 
Plasma fibrinogen levels were compared among the 3 groups. Other variables 
like age, sex, HbA1c, body weight, body mass index, total cholesterol and HDL 
were included.  
Statistical analysis 
Appropriate statistical analyses were made using Graphpad Instat3 software. 
The statistical significance of difference between the mean values of the 
groups were evaluated by Student’s Unpaired ‘t’ Test and Tukey-Kramer 
Multiple Comparisons Test . 
The differences in the mean values of the two groups were regarded as 
statistically significant if the p value was less than 0.05 and highly significant if 
p value was less than 0.01. 
The Baseline Characteristics of the study group is shown in table 1. 
 Group1 Group2 Group3 Total 
Number of patients 40 40 40 120 
Males 26 27 26 79 
Females 14 13 14 41 
Mean age (years) 52.5 ± 5.5 61 ± 7.6 59.5 ± 5.2 57.6 ± 7.2 
Mean body weight (Kg) 65.1 ± 6.1 66.2 ± 4.9 65.0 ± 4.8 65.4 ± 5.3 
Mean Body Mass Index (Kg/m2) 24 ± 2.7 25.1 ± 2.2 24.5 ± 2.5 24.4  ± 2.6 
Hypertension – Yes 16 25 10 51 
No 24 15 30 69 
Table 1 
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Age wise distribution of the study population 
The age wise distribution is shown in table 2. 
 
                            Table 2 
                Age wise distribution 
 
 
Age(in 
years) 
Males Females Total 
41 – 50 16 10 26 
51 – 60 38 20 58 
61 – 70 20 11 31 
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Plasma fibrinogen levels in Diabetes Mellitus 
The mean fibrinogen levels in the 3 groups are given in table 3.The mean 
fibrinogen in patients with DM with macrovascular complication (group3) 
were elevated compared to the other groups. 
 
 DM alone 
(Group 1) 
DM with 
macrovascular 
complication 
(Group2) 
DM with 
microvascular 
complication  
(Group 3) 
Mean fibrinogen 
(mg/dl) 
421.2125 471.3775 471.3775 
Standard 
deviation (SD) 
32.831 17.036 15.610 
Std. error of 
mean(SEM) 
5.191 2.694 2.468 
Lower 95% conf. 
limit 
410.71 465.93 434.55 
Upper 95% conf. 
limit 
431.71 476.83 444.54 
Median(50th 
percentile) 
423.75 469.05 442.35  
Table 3 
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                        Mean plasma fibrinogen levels  
In order to ascertain whether differences between the fibrinogen levels 
among 3 groups were statistically significant, p value was calculated using 
Tukey-Kramer Multiple Comparisons Test. The results are summarized in table 
4.  
Comparison Of Fibrinogen Levels ‘p’ Value 
DM alone & DM with macrovascular 
complications 
p<0.001 (very significant) 
DM alone& DM with microvascular 
complications 
p<0.01 (significant) 
DM with macrovascular and 
microvascular complications 
p<0.001(very significant) 
Table 4 
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The p value is less than 0.01 in all the 3 comparisons indicating that 
differences in the mean fibrinogen levels are significant. Thus fibrinogen levels 
are potential markers of CAD/stroke as well as microvascular complications 
like retinopathy, nephropathy etc.  
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Age & Fibrinogen - Correlation and Regression Analysis: 
In order to assess whether fibrinogen levels vary with age correlation analysis 
were carried out with Pearson formula. The results are as under:  
Correlation coefficient (r) = 0.5808 
95% confidence interval: 0.4481 to 0.6884 
Coefficient of determination (r squared) = 0.3373 
The two-tailed p value is < 0.0001. 
 
 
Thus Fibrinogen levels show a positive correlation with age implying that 
fibrinogen levels increase with age.  
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Fibrinogen levels in Males versus Females 
The mean fibrinogen levels in male and female diabetics are given in table 5. 
   Table 5 
 
                  Mean fibrinogen Levels in males & females   
Though the mean fibrinogen is slightly higher in males than females the p 
value is greater than 0.05 indicating that the differences in male and female 
mean fibrinogen levels is not significant. 
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 Males Females 
Mean fibrinogen  
(mg/dl) 
439.20 ± 27.6 436.47  ± 34.8 
Number 78 42 
‘p‘ value 0.0799 ( not significant) 
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Body Weight & Fibrinogen – Correlation and Regression Analysis 
In order to assess whether fibrinogen levels vary with body weight correlation 
analysis was carried out using Pearson formula. The results are as under: 
Correlation coefficient (r) = 0.6050 
95% confidence interval: 0.4775 to 0.7075 
Coefficient of determination (r squared) = 0.3660 
The two-tailed P value is < 0.0001, considered extremely significant. 
 
Fibrinogen levels show a positive correlation with body weight implying that 
its level increases with increasing body weight.  
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Fibrinogen Levels In Diabetes compared to Diabetes & Hypertension 
The mean fibrinogen levels in patients with diabetes alone and diabetes with 
hypertension are summarized in table 6. 
 DM & SHT DM 
Fibrinogen 
(mg/dl) 
466.7  ± 20.3 428.5  ± 26.9 
Number of 
patients 
49 71 
‘ p ‘  value 0.0400 ( significant) 
                  Table 6 
 
Fibrinogen levels in DM alone and DM with SHT 
 
The p value is less than 0.05 indicating that hypertension is also a factor that 
causes elevation of fibrinogen levels. 
400 
410 
420 
430 
440 
450 
460 
470 
DM DM & SHT 
M
ea
n
 f
ib
ri
n
o
ge
n
 (
m
g/
d
l)
 
54 
 
Fibrinogen and HbA1c 
In order to find out whether glycemic control affected fibrinogen levels ,the 
mean fibrinogen levels in patients with HbA1c > 7% was compared with HbA1c 
< 7% the results are shown in table 7. 
 HbA1c > 7 HbA1c < 7 
Fibrinogen (mg/dl) 460.82 427.56 
Number of patients 61 58 
‘p’ value 0.0118 (significant) 
            Table 7 
 
                           Fibrinogen Levels and HbA1c  
The difference is statistically significant implying that fibrinogen levels 
increases with poor glycemic control. 
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Fibrinogen and HbA1c- Correlation and Regression Analysis 
In order to assess whether Fibrinogen levels varies with HbA1c levels 
correlation analysis was carried using Pearson formula. The results are as 
under: 
Correlation coefficient (r) = 0.6246  
95% confidence interval: 0.5014 to 0.7229 
Coefficient of determination (r squared) = 0.3901 
The two-tailed P value is < 0.01 considered very significant. 
  
The fibrinogen levels show a positive correlation with HbA1c implying 
Fibrinogen levels increase with Increasing HbA1c levels.  
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Body Mass Index and Fibrinogen - Correlation and Regression Analysis 
The Pearson Correlation formula was used.  
Correlation coefficient (r) = 0.5484 
95% confidence interval: 0.4094 to 0.6626 
Coefficient of determination (r squared) = 0.3008 
The two-tailed P value is < 0.0001, considered extremely significant. 
 
 
 
Fibrinogen levels showed a significant positive correlation with Body mass 
index. 
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Fibrinogen and Total Cholesterol (TC) 
The fibrinogen levels in patients having total cholesterol >200 mg/dl was 
compared with patients having total cholesterol < 200mg/dl. The results are 
shown in table 8. 
 
                   Table 8
 
Fibrinogen levels in patients with total cholesterol greater/less than200 mg/dl 
Fibrinogen levels are significantly higher in patients having total cholesterol 
greater 200 mg/dl. 
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 TC > 200 TC < 200 
Mean 
Fibrinogen 
(mg/dl) 
451.67 ± 21.5 422.89 ± 31.8 
Number of 
patients 
73 47 
‘p’ value 0.0028 ( very significant) 
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Total Cholesterol in Diabetes alone versus Diabetes with Complications 
Total cholesterol in the 3 groups of diabetic patients (DM alone, DM with 
macrovascular complications, DM with microvascular complication) were 
compared. The results are shown in table 9. 
 DM  DM with 
macrovascular 
complications 
DM with 
microvascular 
complications 
Mean 
Cholesterol 
202.43  ± 22.597 219.98  ± 18.564   207.68 ±  17.813 
     Table 9 
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The p values were calculated using Tukey-Kramer Multiple Comparisons Test. 
The results are shown in table 10.  
Comparison p value 
DM & DM with macrovascular complications P < 0.01 
DM & DM with microvascular complications P >0.05 
Microvascular & Macrovascular complication P < 0.01 
Table 10 
Total cholesterol is significantly elevated in Diabetic patients with 
macrovascular complications (CAD/CVA) compared to other diabetic patients. 
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HDL Cholesterol In Diabetes Alone Versus Diabetes With Complications 
HDL cholesterol in the 3 groups of diabetic patients (DM alone, DM with 
macrovascular complications, DM with microvascular complications) were 
compared. The results are shown in table 11. 
 DM  DM with 
macrovascular 
complications 
DM with 
microvascular 
complications 
HDL 
Cholesterol 
48.525 ± 3.823 46.850 ± 3.085 48.650 ± 2.806 
Table 11 
The p values were calculated using Tukey-Kramer Multiple Comparisons Test. 
The results are shown in table 12. 
Comparison p value 
DM & DM with macrovascular complications p > 0.05 
DM & DM with microvascular complications p >0.05 
Macrovascular & microvascular complication P > 0.05 
Table 12 
There are no significant differences in the HDL levels among the three groups. 
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DISCUSSION 
The study was a cross sectional study in 120 diabetic patients belonging to 
lower socio-economic group attending Rajiv Gandhi Government General 
Hospital. They were divided into 3 groups of 40 each. Group 1 patients had 
DM without microvascular complications. Group 2 had DM patients with 
macrovascular complications (CAD/CVA). Group 3 had patients with 
microvascular complications. There were 79 males and 41 females. The mean 
age of the study group was 57.6 ± 7.2 years. 42 % of the patients were 
hypertensives. 
The results from this study showed fibrinogen to be significantly higher in 
diabetic patients who  had macrovascular complications like coronary artery 
disease, and cerebrovascular disease than those who had  only diabetes or 
diabetes with microvascular complications like nephropathy, neuropathy 
retinopathy etc.  
The study also showed fibrinogen to be higher in patients with diabetes with 
microvascular complications than those who had diabetes only. Fibrinogen 
levels were also higher in Diabetes than reference values of fibrinogen (200 to 
400 mg/dl39) in the general population. 
“Fibrinogen studies collaboration” - a large meta analysis of  large and 
comprehensive data comprising 6944 first nonfatal myocardial infarction or 
stroke events and 13210 deaths and various other studies have found that 
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increased fibrinogen levels are associated with major systemic morbidity like 
coronary artery disease, stroke etc.56 
 In a study by Bruno et al involving 1574 diabetics in north Italy, fibrinogen 
was found to be significantly elevated in diabetes mellitus patients compared 
to non diabetics.41 Similarly, Jensen et al. reported a progressive increase in 
fibrinogen level in diabetics with complications.42 In a study by  Eriksson et al 
in Stockholm area to assess the relationship between plasma fibrinogen and 
coronary heart disease in women, found the mean value for plasma fibrinogen 
to be significantly higher in patients with coronary artery disease than in 
controls and it tended to be higher in diabetics than in nondiabetics.43 Sanchez 
et al conducted a study to assess the prognostic relations between 
inflammatory markers and mortality in diabetic patients with non ST elevation 
acute coronary syndrome found fibrinogen and WBC count to be higher in 
diabetic than in non-diabetic patients on admission and among diabetic 
patient fibrinogen was higher in those who died during the follow up.44 Similar 
studies by James et al45, Kafle et al46, Taj Muhammad Khan et al49 showed 
fibrinogen to be elevated in diabetics with CAD compared to non diabetics 
with CAD and non diabetics. 
Maresca et al observed elevated fibrinogen as a strong cardiovascular risk 
factor in diabetes mellitus and suggested that it accounts for a part of the 
excessive cardiovascular risk in type 2 diabetic patients that remains 
unexplained after considering the traditional risk factors.40  
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In our study we found that diabetic patients with microvascular complications 
had significant elevation of fibrinogen compared to diabetic patients without 
complications. In a study by Bruno et al involving 1574 type 2 diabetics in 
north Italy, fibrinogen was found to correlate well with albumin excretion 
rate.41 Mattock et al and Neil et al in their studies showed increased 
cardiovascular-related morbidity and mortality in diabetic patients with 
microalbuminuria and macroalbuminuria.50-51 This positive association seen 
between albumin excretion rate and fibrinogen could explain this increased 
cardiovascular risk. 
In a study by Klein et al involving 909 patients with type 1 diabetes enrolled in 
the Diabetes Control and Complications Trial/Epidemiology of Diabetes 
Interventions and Complications (DCCT/EDIC) it was found that fibrinogen 
correlated with albumin excretion rate and its levels were increased in 
patients with peripheral vascular disease and retinopathy but did not 
correlate with severity of retinopathy.52 Asakawa et al and Fujisawa et al have 
shown  that increased fibrinogen is associated with worsening renal function 
and also retinopathy.53-54Recent studies have shown that certain 
polymorphisms in fibrinogen gene is associated with elevated levels of 
fibrinogen in type 2 diabetes mellitus. 
Similar findings have been shown in India by Neetha Kuzhuppilly et al in a 
study at Kasturba Medical College, Manipal, Karnataka.55 
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In our study we found that plasma fibrinogen correlated well with HbA1c 
levels with a correlation coefficient of 0.58. Fibrinogen levels also correlated 
with body mass index, body weight and age. This has been shown in studies by 
Bruno et al41, Klein et al52, Kafle et al.46 
In our study we found that fibrinogen levels were slightly higher in males than 
females though the difference was not significant. This is in contrast to other 
studies by Klein et al52, Jain et al58 where the levels were slightly higher in 
females but the difference was also not significant as in our study. 
Out of the 120 patients 49 patients had hypertension. The mean fibrinogen in 
patients with both diabetes and hypertension were significantly higher than 
diabetes alone. This has been seen various studies58-60This implies that 
hypertension itself is a risk factor for elevated fibrinogen levels and probably 
has a synergestic effect with diabetes mellitus in the development of 
complications. 
The fibrinogen levels were elevated in presence of hypercholesterolemia. In 
our study it was found that mean fibrinogen levels were elevated in patients 
having total cholesterol > 200mg/dl. Similar observations were seen in studies 
by Klein et al and Jain et al.52, 58   
In our study there was no significant relationship between HDL cholesterol 
and fibrinogen levels and development of microvascular complications. This is 
in contrast to Jain et al, Klein et al and Kafle et al where the levels of HDL were 
lower in patients with microvascular and macrovascular complications.42, 52, 58 
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CONCLUSION 
1. A total of 120 cases of diabetes mellitus were involved in the study who 
were divided into 3 groups of 40 each – diabetes alone, diabetes with 
microvascular complications, and diabetes with macrovascular 
complications.  
2. The mean fibrinogen levels in patients with macrovascular 
complications were significantly higher than with microvascular 
complications and diabetes alone indicating that elevated fibrinogen 
levels is risk factor for development of macrovascular complications 
and thus a marker of morbidity and mortality. 
3. The mean fibrinogen levels in patients with microvascular 
complications were significantly higher than diabetes alone and thus it 
is a marker for development of retinopathy, nephropathy etc. 
4. Of the 120 patients, there were 78 males and 48 females. The mean   
fibrinogen levels were slightly higher in males than in females but the 
difference was statically insignificant. 
5. The age group ranged from 42 to 73 years. The plasma fibrinogen levels 
correlated well with age, body weight and body mass index indicating 
higher levels with older age and obesity. 
6. The plasma fibrinogen levels correlated well with HbA1c levels 
indicating poor glycemic control is risk factor for developing elevated 
levels of fibrinogen. 
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7. The mean plasma fibrinogen levels were significantly higher in diabetic 
patient associated with hypertension than with diabetes alone. 
8. Fibrinogen levels were significantly higher in patients with total 
cholesterol > 200 than with total cholesterol < 200. 
9. There were no significant differences in mean HDL cholesterol level 
among the patients with diabetes alone, diabetes with microvascular 
complication. 
10. The results of study indicate that plasma fibrinogen levels is an 
important risk factor for developing macrovasular complications mainly 
coronary artery disease and cerebrovascular accidents as well as 
microvascular complications like retinopathy, nephropathy . Fibrinogen 
levels also increases with age, body weight, hypertension, poor 
glycemic control and dyslipidemia. 
11. From our study we can recommend estimation of fibrinogen in a subset 
of patients who have poor glycemic control, hypertension, obesity and 
if fibrinogen levels are found high strict control measures should be 
initiated. 
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FUTURE TRENDS 
1. Further studies on the existing modalities which lower fibrinogen and 
finding newer treatment measures that can lower the fibrinogen levels 
without adverse effects, should be done. 
2. Fibrinogen levels before initiating treatment and during on-going treatment 
could be a potential indicator for overall efficacy of therapy and life style 
modifications and the risk reduction. 
3. Fibrinogen levels could be a potential marker for the prediction and 
prevention of macrovascular or microvascular complications. 
4. Recent studies have shown that certain polymorphisms of fibrinogen genes 
are associated with elevated fibrinogen levels. The occurrence of these 
polymorphisms needs to be studied in Indian population. 
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LIMITATION OF STUDY 
1. The results were predominantly obtained from a cross-sectional survey 
of small number of patients. Patients recruited here may not be 
representative of the entire population. 
2. The duration of diabetes was not considered. 
3. The sample did not include patients with type 1 diabetes mellitus. 
4. Retinopathy could not be assessed in significant number of patients 
since they had cataract. The severity of retinopathy was not used for 
analysis. 
5. The proteinuria was not quantified. The presence of microalbuminuria 
or macroalbuminuria was taken as the evidence of nephropathy. 
6. The effect of treatment modality (insulin, oral hypoglycemic agents or 
both) could not be compared with fibrinogen levels as most patients 
were taking drugs irregularly without regular follow up. 
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PROFORMA 
FIBRINOGEN LEVELS IN DIABETES MELLITUS 
Name:                                                       Age:                   Sex: 
Address: 
 
Mobile number: 
Unit/Ward: 
 
PRESENT HISTORY 
DURATION OF DIABETES : 
Symptoms 
Polyuria                                    Oliguria                                    Visual disturbances 
Polydipsia                                 Facial puffiness                       Weight loss/gain 
Polyphagia                               Swelling of legs                        High coloured Urine 
Giddiness                                 Anorexia                                   Headache/loc/fits 
Chest pain                                Vomiting/hiccups                     Sensory disturbances 
Palpitations                              Easy fatiguablity                      Leg ulcers 
Breathlessness                        Altered bowel habits                Limb weakness 
Fever                                        Dysuria                                      Abdominal pain 
  
PAST HISTORY 
SHT                                               CAD                                           KIDNEY DISEASE 
CVA                                               SEIZURE DISORDER                  PT 
HYPOGLYCEMIC EPISODES 
OTHERS 
TREATMENT HISTORY: 
 
 
 
 
 
 
COMPLIANCE : GOOD / POOR 
PERSONAL HISTORY: 
ALCOHOL:  
DIET : 
LIFE STYLE : ACTIVE / SEDENTRY 
 
  
CLINICAL EXAMINATION 
WEIGHT:                          HEIGHT:                       BMI: 
VITALS 
PULSE 
BP 
GENERAL EXAMINATION 
CVS 
 
RS 
 
ABDOMEN 
 
CNS 
 
FUNDUS: 
  
INVESTIGATIONS: 
URINE ANALYSIS 
Albumin  
Sugar 
Deposits 
COMPLETE HEMOGRAM 
HB (G/DL) 
TC (CELLS/CMM) 
DC 
ESR 
PLATELET(LAKHS/CMM) 
 
RENAL FUNCTION TESTS 
BLOOD SUGAR (RANDOM) 
BLOOD UREA(MG/DL) 
S. CREATININE(MG/DL) 
FASTING PLASMA GLUCOSE: 
POST PRANDIAL PLASMA GLUCOSE: 
HBA1C: 
 
ECG IN ALL LEADS: 
  
 
CHEST X RAY PA VIEW: 
 
 
 
ECHOCARDIOGRAPHY: 
 
ULTRASONOGRAPHY: 
FIBRINOGEN: 
 
HDL:                                                   TOTAL CHOLESTEROL: 
S.
N
O
 
N
A
M
E 
A
G
E 
SE
X
 
W
EI
G
H
T
 
B
M
I 
SH
T
 
C
V
A
 
C
A
D
 
R
ET
IN
O
P
A
TH
Y
 
N
EP
H
R
O
P
A
TH
Y
 
N
EU
R
O
P
A
TH
Y
 
H
b
A
1
c 
FI
B
R
IN
O
G
EN
 
TO
TA
L 
C
H
O
LE
ST
E
R
O
L 
H
D
L 
1 Arumugam 49 m 70 26 y n n n n n 7.3 483 226 46 
2 Manokaran 49 m 76 28 y n n n n n 8.2 483.5 243 42 
3 Arunagiri 53 m 65 23 n n n n n n 6.9 423.7 190 50 
4 Jayanthi 50 f 58 22 n n n n n n 7.2 365.7 178 47 
5 Muruganathan 58 m 68 24 y n n n n n 7.5 460.5 200 45 
6 Ramasamy 54 m 63 23 n n n n n n 6.7 398.9 180 49 
7 Sargunam 55 f 59 24 y n n n n n 7 411.8 178 53 
8 Mayavel 45 m 63 22 n n n n n n 7.9 433.1 200 52 
9 Narayanan 57 m 72 26 y n n n n n 7.5 448 203 45 
10 Saraswathy 49 f 55 23 n n n n n n 7.1 359.1 169 47 
11 Ramakrishnan 47 m 64 21 n n n n n n 6.7 414.7 183 49 
12 Mukundan 55 m 68 24 y n n n n n 7 432.7 200 48 
13 Sundari 57 f 64 23 n n n n n n 7.3 400.3 188 52 
14 Shanmugam 47 m 66 23 n n n n n n 7 417.5 196 45 
15 Srinivasan 54 m 70 26 y n n n n n 7.5 440 233 56 
16 Ansar Basha 50 m 67 23 y n n n n n 7.3 439.1 240 55 
17 Madhavan 56 m 65 24 n n n n n n 7.2 414.4 189 56 
18 Bakkiyam 50 f 56 20 n n n n n n 6.8 375.5 190 45 
19 Aravindan 44 m 62 23 n n n n n n 6.6 417.3 188 51 
20 Rahima Begum 56 f 68 27 y n n n n n 7.7 438.9 212 45 
21 Chakravarthy 56 m 84 28 y n n n n n 8.9 468.5 256 49 
22 Kuppusamy 59 m 67 25 n n n n n n 7.9 423.8 208 46 
23 Lakshmanan 48 m 65 22 n n n n n n 6.7 400.7 176 53 
24 Rosy 64 f 67 27 n n n n n n 7.3 421.4 211 55 
25 Munusamy 57 m 63 21 n n n n n n 7.5 428.9 209 43 
26 Arokiadas 48 m 58 19 n n n n n n 6.4 370.6 176 45 
27 Ravikumar 50 m 61 21 n n n n n n 6.8 426 202 47 
28 Laxmiammal 58 f 60 28 y n n n n n 8.5 443.1 232 48 
29 Janaki 43 f 55 21 n n n n n n 6.4 358.3 178 53 
30 Krishnan 42 m 60 22 n n n n n n 6.8 390.7 198 56 
31 Nirmala 60 f 67 27 y n n n n n 8.9 452.8 223 48 
32 Manimaran 54 m 69 24 y n n n n n 6.9 444.6 211 47 
33 Rajendran 55 m 60 20 n n n n n n 7 392.4 177 44 
34 Kotti 63 m 69 25 y n n n n n 7.8 450.2 234 46 
35 Noshin 47 f 57 22 n n n n n n 6.6 360.4 166 49 
36 Kanchana 46 f 63 28 n n n n n n 7.4 410.5 198 51 
37 Arumugam 50 m 66 23 n n n n n n 6.6 404 188 53 
38 Sarasu 55 f 63 25 n n n n n n 8.1 430.1 222 53 
39 Loganayaki 49 f 68 29 y n n n n n 7.9 454 235 49 
40 Srinivasalu 60 m 79 29 y n n n n n 8.8 459.8 211 48 
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1 Mookaiah 67 m 67 24 y y n n n n 8.9 481.6 223 45 
2 Raja 63 m 69 24 y y n n y n 8.6 477 218 43 
3 Geethalakshmi 68 f 66 28 y y y y y y 9 483.4 245 46 
4 Kamaraj 58 m 63 24 y n y n n n 7.9 475.1 212 47 
5 Ansar Basha 70 m 72 27 y y y y y y 9.2 513 243 47 
6 Sumithra 63 f 66 28 y n y y y n 7.7 463.8 221 42 
7 Kumar 51 m 65 24 y n y n n n 7.4 461 200 49 
8 Kannikammal 66 f 64 26 y y n y y y 8.4 461.9 243 50 
9 Narasimman 65 m 67 25 y n y n n n 7.1 466.2 211 53 
10 Nissar Ahmed 67 m 78 27 y y y n n n 7.8 498.4 209 45 
11 Sumathi 56 f 59 23 n n y n n n 7 452.8 212 46 
12 Raman 49 m 67 24 n n y n n n 7.4 460 234 43 
13 Arul 55 m 58 21 n n y n n n 7.6 440.1 189 44 
14 Neelavathi 59 f 59 24 y y n y y n 7.4 470.1 198 45 
15 Suresh 49 m 70 27 y n y n n n 8.3 475 202 47 
16 Duraisamy 69 m 72 26 y y n y y y 9 502 255 48 
17 Arunan 75 m 70 27 y y y y y y 8.9 511.2 221 42 
18 Arumugam 57 m 65 24 y n y n n n 8.1 471.5 200 45 
19 Devika 55 f 58 23 n y n n n n 7 439.5 202 50 
20 Murugesan 60 m 67 26 n n y n n n 6.8 462.3 215 54 
21 Rangan 70 m 65 24 n n y y n n 7.6 466.8 236 46 
22 Senthamarai 70 f 67 27 y y n y y n 8.9 494.6 254 47 
23 Nathamuni 66 m 76 29 y y y n n y 9.3 480 232 45 
24 Venda 50 f 58 25 n n y n n n 7.4 450.4 213 43 
25 Lakshmi 58 f 65 29 y y n n n n 8.6 464.2 246 47 
26 Subramani 67 m 70 24 n n y n n n 6.9 456.3 221 49 
27 Ramamoorty 59 m 68 24 n y n n n n 7 453.5 189 51 
28 Arjunan 54 m 65 23 y y n n y n 9.2 478.2 234 46 
29 Noornisha 65 f 67 28 y y y y y n 8.8 489.9 245 51 
30 Kumaran 70 m 73 25 n y n n n n 7.2 468.3 201 47 
31 Palayam 72 m 59 21 y y n y y y 8.8 489.8 200 48 
32 Rajeshwari 50 f 66 28 y n y n n n 7.8 470.1 234 43 
33 Vishwanathan 58 m 67 23 n n y n n n 8 460.3 215 44 
34 Damodaran 64 m 59 19 y n y y y n 8.5 469.8 203 46 
35 Moorthy 50 m 68 26 n y n n n n 6.9 464.6 224 45 
36 Suseela 69 f 65 26 y y n n n n 8.4 481.3 234 52 
37 Nirmala 48 f 59 24 n n y n n n 8.8 450.9 214 53 
38 Ahmad 67 m 73 25 n n y n n n 7.8 463.2 219 48 
39 Sambandam 60 m 67 24 n y n n n n 7.3 467 189 47 
40 Shanmugam 51 m 69 27 y n y n n n 7.8 470 243 45 
  1 aravindan 55 m 64 22 n n n y y n 7.4 435.5 221 43 
2 nagaraj 66 m 73 27 y n n y y y 7.9 455 238 45 
3 chandra 57 f 59 24 n n n y y n 7.3 410.8 222 47 
4 fathima 53 f 66 29 n n n y y y 8.4 442.5 200 48 
5 vijaya 65 f 68 27 y n n n y y 8.9 453.4 212 45 
6 moorthy 62 m 65 23 n n n Y y  7.9 442.2 194 46 
7 shankar 59 m 67 24 n n n n y y 6.9 438 188 46 
8 manimaran 59 m 63 23 y n n y y n 7.5 465.7 197 49 
9 kumari 66 f 67 26 n n n y n y 8.3 442.7 221 50 
10 gopi 58 m 66 25 n n n y y n 7.4 435.7 212 51 
11 saroja 65 f 61 26 n n n y y y 7.5 433.9 214 56 
12 sundar 58 m 66 22 n n n y y n 7.2 440 242 46 
13 janakiraman 63 m 59 21 n n n n n n 7.3 416 200 48 
14 murali 53 m 67 24 n n n y y y 7.8 450.6 219 49 
15 robert 58 m 70 26 n n n n y y 8.5 441.2 211 50 
16 abdul 72 m 67 26 n n n y y y 8.8 443.7 231 53 
17 praveena 53 f 58 21 n n n n y n 7.1 421.8 198 52 
18 gowri 68 f 69 28 y n n y y y 7.8 448.4 221 48 
19 thangaraj 57 m 59 21 n n n y y n 6.8 426.8 221 49 
20 poorani 57 f 59 21 n n n y y y 7.5 417.9 243 46 
21 raju 69 m 75 27 n n n y y y 7.8 460.2 231 48 
22 shanmugam 58 m 65 24 n n n y n n 7.9 443.7 189 45 
23 surenderan 63 m 69 26 y n n y y y 8.2 467.8 221 47 
24 naseer 54 m 66 26 n n n y y n 7.6 443.6 201 54 
25 selvi 55 f 59 23 n n  n y y n 7.8 407.6 197 52 
26 david 56 m 60 20 n n n n y n 6.9 424.6 176 49 
27 lakshmi 59 f 58 23 n n n y y n 7.8 436.8 189 49 
28 muruganathan 55 m 62 21 n n n n y n 6.9 423.5 198 47 
29 munusamy 67 m 70 24 n n n y y y 9.3 453.7 189 48 
30 suganthy 63 f 67 27 y n n y y y 9.5 450.8 211 48 
31 kalimuthu 68 m 64 26 n n n y y n 7.8 445.7 211 47 
32 saraswathy 57 f 69 28 n n n y y y 8.9 448.5 219 48 
33 alexander 55 m 73 29 y n n y y y 9.4 468.8 211 46 
34 duraisamy 58 m 69 26 n n n y y n 8.3 443.4 198 46 
35 rajan 49 m 59 21 n n n n y n 7 430.8 189 53 
36 meenakshi 56 f 59 23 n n n n y n 7.2 406.5 178 51 
37 sukumar 59 m 65 24 y n n y y y 9.6 448.4 198 53 
38 mohan 59 m 68 25 n n n n y n 7.2 438.6 187 49 
39 nirmala 55 f 58 21 n n n n y n 7.3 420.5 178 49 
40 raziya 60 f 73 28 n n n y y y 9.6 450.7 231 50 
PATIENT CONSENT FORM 
Study detail: 
                     “STUDY ON FIBRINOGEN LEVELS IN TYPE 2 DIABETES MELLITUS” 
Study centre  :             Rajiv Gandhi Government general hospital, Chennai. 
 
Patients Name  : 
Patients Age  : 
Identification Number        : 
   Patient may check (     ) these boxes 
I   confirm that I have understood the purpose of procedure for the above study. I have the 
opportunity to ask question and all my questions and doubts have been answered to my complete 
satisfaction. 
I understand that my participation in the study is voluntary and that I am free to withdraw at any time 
without giving reason, without my legal rights being affected. 
I understand that sponsor of the clinical study, others working on the sponsor’s behalf, the ethical 
committee and the regulatory authorities will not need my permission to look at my health records, 
both in respect of current study and any further research that may be conducted in relation to it, even 
if I withdraw from the study I agree to this access. However, I understand that my identity will not be 
revealed in any information released to third parties or published, unless as required under the law. I 
agree not to restrict the use of any data or results that arise from this study. 
I agree to take part in the above study and to comply with the instructions given during the study and 
faithfully cooperate with the study team and to immediately inform the study staff if I suffer from any 
deterioration in my health or well being or any unexpected or unusual symptoms. 
I hereby consent to participate in this study. 
I hereby  give permission to undergo complete clinical examination and diagnostic tests including 
hematological, biochemical, radiological tests. 
Signature/thumb impression:    
Patients Name and Address:                   Place   Date 
 
Signature of investigator :    
Study investigator’s Name :                               Place   Date      
 
